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ABSTRACT
Cell differentiation is a central process in develop-
ment and in cancer growth and dissemination. OCT4
(POU5F1) and NANOG are essential for cell stem-
ness and pluripotency; yet, the mechanisms that
regulate their expression remain largely unknown.
Repetitive elements account for almost half of the
Human Genome; still, their role in gene regulation
is poorly understood. Here, we show that the dioxin
receptor (AHR) leads to differentiation of human
carcinoma cells through the transcriptional upreg-
ulation of Alu retrotransposons, whose RNA tran-
scripts can repress pluripotency genes. Despite the
genome-wide presence of Alu elements, we pro-
vide evidences that those located at the NANOG
and OCT4 promoters bind AHR, are transcribed by
RNA polymerase-III and repress NANOG and OCT4
in differentiated cells. OCT4 and NANOG repression
likely involves processing of Alu-derived transcripts
through the miRNA machinery involving the Micro-
processor and RISC. Consistently, stable AHR knock-
down led to basal undifferentiation, impaired Alus
transcription and blockade of OCT4 and NANOG re-
pression. We suggest that transcripts produced from
AHR-regulated Alu retrotransposons may control the
expression of stemness genes OCT4 and NANOG
during differentiation of carcinoma cells. The control
of discrete Alu elements by specific transcription fac-
tors may have a dynamic role in genome regulation
under physiological and diseased conditions.
INTRODUCTION
Recent evidences suggest that active transposable elements
(TEs) have an important role in defining Human Genome
structure and function and, consequently, in controlling de-
velopment and disease (1,2). Short interspersed nuclearAlu
elements (SINE) are a class of TEs highly abundant in the
Human Genome that account for nearly 10% of its size (3).
Alu retrotransposons derive from the 7SL RNA and are
highly abundant in non-coding genomic regions including
upstream promoters and gene introns (4,5). Previous stud-
ies have shown that global transposon activity varies under
diverse cellular conditions; yet, very little is known regard-
ing the mechanisms through which TEs regulate the expres-
sion of specific genes (6). In this context, a recent study re-
vealed that an Alu element inserted in human chromosome
9p21 within the long non-coding RNA (lncRNA) ANRIL
was needed to trans-regulate genes presumably involved in
atherosclerosis (7). In the mouse, Anril lncRNA regulated
cell proliferation and differentiation through theCdkn2A/B
gene (8).
Notably, TEs are potential carriers of binding sites for
transcription factors. Genome-wide analyses have found
an enrichment of binding sites for ESR1, TP53, OCT4
(POU5F1), SOX2 and CTCF in human TEs (9–11). In fact,
TEs provide up to 25% of the binding sites for the pluripo-
tency regulators OCT4 (POU5F1) and NANOG and for
the chromatin remodeler CTCF in both human and mouse
embryonic stem (ES) cells (10). Consequently, it appears
plausible that TEs assume an important role in the control
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of transcriptional programs that regulate cell turnover and
plasticity (10). Furthermore, certain classes of TEs were up-
regulated whereas others were downmodulated during the
reprogramming of differentiated cells into induced pluripo-
tent stem (iPSc) cells, thus producing an expression profile
reminiscent of that of ES cells (12,13). Overall, these for-
mer studies suggest that TEs could modulate specific tran-
scriptional programs that drive pluripotency and cell repro-
gramming (12). Previous work from our laboratory iden-
tified a novel B1-SINE retrotransposon (B1-X35S) widely
represented in upstream regulatory regions of the mouse
genome that acts as a genomic insulator blocking target
gene expression (14,15). B1-X35S-dependent insulation re-
quired the interaction of transcription factors dioxin recep-
tor (AhR) and Slug (Snai2) with their consensus sequences
present in B1-X35S and the transcriptional activity of RNA
polymerases III and II (15,16).
It is becoming increasingly clear that some repetitive ele-
ments are relevant for cell functioning. Recent efforts have
identified repetitive sequences with the potential to regu-
late gene expression and to participate in the control of
specific cell processes under normal and pathological con-
ditions (15,17–19). In this work, we have investigated the
functional relevance of Alu retrotransposons regulated by
the dioxin receptor AHR in the differentiation of human
embryonic carcinoma cells. We have focused on individ-
ual Alu elements located in the upstream regulatory re-
gions of pluripotency genes NANOG and OCT4. AHR ex-
erted a pro-differentiation role that was responsible, at least
in part, for the repression of OCT4 and NANOG. Inter-
estingly, such repressive mechanism appears to be medi-
ated by non-coding RNA transcripts produced by RNA
polIII from the Alu elements following AHR binding. In
fact, the NANOG Alu was able to repress the expression
of both OCT4 and NANOG in the absence of a differen-
tiating stimulus. Among the mechanisms that could repress
NANOG and OCT4 in differentiated carcinoma cells, pro-
cessing and loading ofNANOGAlu-derived transcripts into
the miRNAmachinery appears as a plausible possibility. In
sum, we suggest that individual Alu retrotransposons could
have a causal role in the control of complex cellular func-
tions such as differentiation and pluripotency. The regula-
tory mechanism proposed here could also contribute to es-
tablish gene expression programs required for cellular re-
programming and for the maintenance of an undifferenti-
ated state.
MATERIALS AND METHODS
Antibodies
The following antibodies were used: III-tubulin (Santa
Cruz Biotechnology sc-58888, clone TUJ-1), GAP43 (Milli-
pore AB-5220), Tau (generous gift of Dr Lorenzo-Benayas,
University of Extremadura), GAPDH (Cell Signaling 2118,
clone 14C10), OCT4 (Santa Cruz Biotechnology sc-5279,
clone C-10), NANOG (AbCam Ab-21624), AGO2 (Milli-
pore 03–110), AHR (ENZOLife Sciences BML-SA210 and
Immunostep 130605–1) and -Actin (Sigma A2066).
Cells lines and reagents
Human embryonic teratocarcinoma NTERA-wt and
NTERA-sh cells were cultured in DMEM containing 10%
FBS, 100 U/ml penicillin, 100 g/ml streptomycin and
2 mM L-glutamine at 37◦C and 5% CO2 atmosphere.
NTERA-wt and NTERA-sh cell lines were authenticated
by DNA profiling using 8 different and highly polymorphic
short tandem repeat (STR) loci (German Biological Re-
source Centre DSMZ). H9 human ES cells were cultured in
matrigel-coated culture plates in high glucose Dulbecco’s
modified Eagle’s medium (DMEM) knockout medium
containing knockout serum replacement, L-glutamine and
non-essential aminoacids at 37◦C in a 5% CO2 atmosphere.
Cells were tested to be mycoplasma free using the Look-
Out Mycoplasma detection kit (Sigma). Protein A/G-plus
agarose was from Santa Cruz Biotechnology. The iScriptTM
Reverse Transcription Supermix was from Bio-Rad and the
SYBRR© Select Master Mix was from Life Technologies.
The AhR agonist 6-formylindolo[3,2-b]carbazole (FICZ)
was from Enzo.
Retroviral knockdown of human AHR
AHR was knocked-down in NTERA cells by retroviral
transduction essentially as described (20,21) using the sh-
RNA sequence 5′ TGCTGTTGACAGTGAGCGAGCA
ATGAATTTCCAAGGGAAGTAGTGAAGCCAC
AGATGTACTTCCCTTGGAAATTCATTGCCTGCCT
ACTGCCTCGGA 3′. For rescue experiments, an shRNA
was synthesized targeting the 3′UTR region of the human
AHR: 5′ TGCTGTTGACAGTG
AGCGAACTCTTTACCTTTATTGATATTAGTGA
AGCCACAGATGTAATATCAATAAAGGTAAAGA
GTGTGCCTACTGCCTCGGA 3′. shRNAs sequences
were designed using the algorithm available at: http://www.
stanford.edu/group/nolan/retroviral systems/retsys.html.
Bioinformatic analysis ofAlu elements containingAHRbind-
ing sites
The Human Genome was analyzed for the presence of con-
served elements containing an XRE site and an E-box us-
ing the algorithm previously described (14). Two of the
most abundant groups of elements (e.g. X36S and X45S)
were analyzed for their presence in the 5′promoter region of
pluripotency and stemness genes within a 200-bp interval
from the transcription start site. The background expres-
sion ofNANOG andOCT4 Alus was estimated by referring
the RNA Seq data under basal cell conditions (untreated
NTERA-wt cells) to the total number of AluSq and AluSx
elements identified in the Human Genome.
Chromatin immunoprecipitation (ChIP)
Chromatin immunoprecipitation (ChIP) and double-
sequential ChIP for AHR and OCT4 binding to the
NANOG and OCT4 Alus were performed in NTERA-wt
cells essentially as described (15,22). NTERA-sh cells were
used as negative controls for ChIP experiments.
 at Edinburgh U
niversity on M
ay 24, 2016
http://nar.oxfordjournals.org/
D
ow
nloaded from
 
Nucleic Acids Research, 2016 3
RNA immunoprecipitation (RIP)
RNA immunoprecipitation (RIP) for NANOG Alu-T1
and Alu-T2 loading into AGO2 was done essentially as
described (23). Briefly, NTERA-wt cells were lysed in
polysome lysis buffer containing RNase and protease in-
hibitors. Pre-washed protein-A/G plus agarose was incu-
bated overnight at 4◦C with 5 g anti-AGO2 antibody or
the same amount of IgG. After washing, the mRNP lysate
was added and the mix briefly centrifuged to obtain the in-
put fraction in the supernatant. Reactions were then gen-
tly rotated at room temperature for 2 h, washed and incu-
bated for 30 min in NT2 buffer containing sodium dodecyl
sulphate and proteinase K. RNA was phenol-chloroform-
isoamyl alcohol extracted and ethanol precipitated. RIP
was analyzed by qPCR using the oligonucleotides indi-
cated in Supplementary Table S1. Polymerase chain reac-
tion (PCR) reactions were also analyzed in agarose gels to
determine the presence of the expected product.
RNA sequencing (RNAseq)
RNA sequencing (RNAseq) was performed in NTERA-
wt and NTERA-sh cells in presence or absence of 1 M
RA. Libraries were made using RNA molecules of 75–250
bases in length isolated from agarose gels. Libraries were se-
quenced in an Illumina MiSeq equipment, which produced
8.32, 5.92, 7.70 and 8.79 million lectures for NTERA-wt
(UT), NTERA-wt (RA), NTERA-sh (UT) and NTERA-
sh (RA), respectively. FASTQ raw reads were transformed
into FASTA format using a custom Perl script available on
request. These 75-bp FASTA reads were integrated into a
database, and NCBI Blast was applied using OCT4 and
NANOG Alu full-length sequences as query. Search param-
eters were adjusted for the detection of sequences with the
highest similarity, and normalized against the values ob-
tained for standardAlu elements.When the analysis of iden-
tical sequences was required, ad hoc Perl scripts compar-
ing specific sequences against the full Human Genome se-
quence were used.
Synthesis and cloning of NANOG and OCT4 Alus and
3′UTR sequences
Wild-type NANOG and OCT4 Alu elements and NANOG
Alus mutated in the XRE site and/or A + B boxes were
synthesized by GenScript and cloned in the promoter-less
pUC57 vector. NANOG mRNA 3′UTR was amplified us-
ing the primers indicated in Supplementary Table S1 and
cloned in the pGL2-Basic-Luc vector.NANOG 3′UTRmu-
tants lacking the homology sequences for Alu-T1 and/or
Alu-T2 were constructed by PCR from the wild-type se-
quence and cloned in the pGL2-Basic-Luc vector. The
pUC57 vector does not contain any promoter and it is
therefore indicated to assay the endogenous transcription
of NANOG and OCT4 Alus by RNA polIII.
Mouse teratoma induction
Swiss male immunodeficient mice at 8–10 weeks of age
(Charles Rives) were used for teratoma induction. Mice ex-
perimentation was approved and followed the regulation
established by the Bioethics and Biosecurity Commission
of the University of Granada. Teratoma assays were per-
formed as described previously (24). Briefly, aliquots of 106
exponentially growing NTERA-wt and NTERA-sh cells
were injected subcutaneously in the flank of the neck of each
mouse. Two experiments of twomice were done for each cell
line. After 7–8 weeks, the mice were killed and the tumors
extracted, fixed in buffered formalin, embedded in paraffin
and sectioned. Sections were stained with antibodies for the
three germinal layers: endoderm (pan-cytokeratins and -
fetoprotein), mesoderm (-smooth muscle actin) and ecto-
derm (acidic fibrilar acidic protein). Immunohistochemistry
sections were analyzed blinded by eight different investiga-
tors and the intensity of staining estimated on a 0–10 scale.
Transient transfection
NANOG and OCT4 Alu transposons, DROSHA and
DGCR8 dominant negative mutants (25) and NANOG
3′UTR plasmids were purified and transiently trans-
fected in NTERA-wt or NTERA-sh cells using FuGene 6
(Promega). Aliquots of 1 g DNA were used for the trans-
fections essentially as described (14). Transfection contin-
ued for 48 h in experiments analyzing the expression of
NANOG and OCT4 Alus or for 36 h in luciferase activity
assays. H9 cells were transiently transfected with the AHR
sh-RNA sequence indicated above using the Human Stem
Cell Nucleofector kit in an Amaxa equipment (A-23 pro-
gram) following the recommendations of the manufacturer.
Luciferase activity assays
NANOG 3′UTR constructs were amplified by RT-PCR
from cellular RNA using the oligonucleotides indicated in
Supplementary Table S1. The amplified 3′UTR was cloned
in the XhoI-KpnI sites of the pGL2-Basic vector contain-
ing the firefly luciferase gene. This 3′UTR sequence was fur-
ther modified by PCR to delete the homology region for
NANOG Alu-T1, Alu-T2 or both. 3′UTR constructs were
co-transfected with the pRLTK (renilla luciferase) vector
to normalize luciferase activity. Firefly and renilla luciferase
activities were measured after 36 h using the Dual Glow kit
(Promega) in a Varioskan Flash luminometer (Thermo).
Nuclear and cytosolic cell extracts and immunoblotting
Sodium dodecyl sulphate-polyacrylamide gel electrophore-
sis and immunoblotting were performed using NTERA-wt
and NTERA-sh cell extracts as indicated (21). Nuclear and
cytosolic cellular extracts were prepared from both cell lines
as described (26).
Immunofluorescence
Immunofluorescence was done in anOlympus FV1000 con-
focal microscopy on cultures fixed for 20 min at room tem-
perature in 4% paraformaldehyde (Polysciences Inc.). Flu-
orochromes used were Alexa 488 (NANOG, OCT4, III-
tubulin) andAlexa 633 (AHR, Tau andGAP43). DAPI was
used to stain cell nuclei. Fluorescence distribution was an-
alyzed using the FV10 software (Olympus).
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Reverse transcription and real-time RT-qPCR
Total RNA was isolated from NTERA-wt and NTERA-sh
cells using the RNeasy kit (Qiagen). Reverse transcription
was performed with random hexamers and the iScriptTM
Reverse Transcription Supermix (Bio-Rad). qPCR was
done using SYBRR© Select Master Mix (Life Technologies)
in a Step One equipment (Life Technologies). The oligonu-
cleotides used forRT-qPCRare indicated in Supplementary
Table S1. Conventional (no quantitative PCR) was done us-
ing BiotaqDNApolymerase in a Bio-Rad T100 equipment.
Clone formation assay
Clonogenic assays in 2D were done by platting 103
NTERA-wt and NTERAsh cells in 35 mm plain tissue cul-
ture dishes basically as described (20). After 7 days, the
medium was removed and clones washed in PBS, pho-
tographed and counted using the ImageJ software (version
1.45S).
Flow cytometry
The analysis and separation of cancer stem-like cells
in NTERA-wt and NTERA-sh cultures was done in a
MoFlo-XDP equipment (Beckman-Coulter) essentially as
described (20). Both cell lines were stained for 10 min at
10◦C with antibodies specific for CD133+ (CD133-PE),
CD44+ (CD44-PerCP) and CD29+ (CD29-FITC). To-Pro
(0.1 M) was used to discriminate dead cells from the anal-
yses. Cell cycle distribution was determined essentially as
described (27).
Sphere formation assay
NTERA-wt and NTERA-sh cells were plated in Nunc
ultra-low adherence 24-well plates (Thermo Fisher) at 3 ×
104 cells/well and spheres allowed to form for 24 h. Im-
ages were acquiredwith anOlympusCell-Rmicroscope and
sphere number and size quantified using the ImageJ soft-
ware (version 1.45S).
Transposition assays
For transposition assays, 2 × 104 cells/35 mm2 plate were
co-transfectedwith the driver vector pCEPL1SM-NN (con-
taining a LINE-1) and the pBSKS-NeoIII vector harboring
theNANOGor the OCT4Alu elements. Transfectants were
selected by culturing with 400 g/ml G418 for 12–13 days.
DNA sequencing
NANOG Alu-T1 and Alu-T2 ncRNA transcripts were se-
quenced using the oligonucleotides indicated in Supplemen-
tary Table S1 in anApplied Biosystems 3130 automatic cap-
illary sequencer.
Statistical analyses
Comparison between experimental conditions was done us-
ing GraphPad Prism 6.0 software (GraphPad). Unpaired
two-sided Student’s t-test was used to analyze differences
between two experimental groups. Differences between
three or more experimental conditions were analyzed us-
ing ANOVA. Data are shown as mean ± SD. Differences
were considered significant at *P < 0.05; **P < 0.01; ***P
< 0.001. Data analyses are indicated in the figure legends.
RESULTS
AHR knockdown leads to an undifferentiated phenotype and
blocks RA-induced differentiation of human carcinoma cells
To investigate the implication of AHR in cell differentia-
tion, we have used human pluripotent embryonic terato-
carcinoma NTERA2 cells (NTERA) because they can be
differentiated in culture by the addition of the endogenous
molecule retinoic acid (RA) and because they can be genet-
ically engineered to modulate target gene expression (28–
30). Consistent with their pluripotent phenotype, treatment
of NTERA cells growing at low cell density with RA pro-
duced highly compact clones (Figure 1A) having increased
expression of the neuronal markers Tau, III-tubulin and
GAP43 (Figure 1B and C). This differentiation phenotype
of NTERA cells is consistent with that reported in previ-
ous studies (29). Notably, total cellular levels of AHR sig-
nificantly increased during RA-induced differentiation of
NTERA cells (Figure 1D), suggesting a role for this recep-
tor in the process. To test this hypothesis, we used retrovi-
ral transduction to stably knockdown AHR expression in
NTERA cells by means of short hairpin RNAs (NTERA-
sh). This experimental approach was very efficient in reduc-
ing AHR protein to very low levels in basal and RA-treated
cells (Figure 1D). To avoid caveats derived from the use of
retrovirally-transduced cells, we decided toworkwith a pool
of NTERA cells after puromycin selection rather than us-
ing individual interfered clones. AHR depletion produced
spread clones (Figure 1A) with a significant reduction in
the expression of neuronal markers Tau, III-tubulin and
GAP43 (Figure 1B and C). Moreover, AHR depleted cells
had an almost negligible response to RA-induced differ-
entiation (Figure 1A–C). The undifferentiated phenotype
caused by AhR downmodulation in basal and RA-treated
NTERA cells was not associated with significant changes
in cell cycle distribution as determined by FACS analysis
(Supplementary Figure S1A). Previous reports have shown
that AHR depletion could be relevant for mouse ES cell
maintenance (31) and for mouse melanoma cells to develop
an undifferentiated and metastatic phenotype (20,32). In
agreement, AHR-depleted NTERA-sh cells had increased
levels of stem-like markers CD44+/CD133+/CD29+, more
potential to form spheres under low attachment growing
conditions and reduced levels of differentiation-related de-
hydrogenase activity than wild-type NTERA cells (Supple-
mentary Figure S1B–G). Altogether, these data suggest that
AHR is involved in NTERA differentiation.
Differentiation promotes AHR nuclear accumulation and re-
presses pluripotency genes OCT4 and NANOG
We next explored if the differentiation-dependent increase
in AHR levels could lead to changes in its intracellular dis-
tribution. RA treatment promoted a robust nuclear accu-
mulation of AHR in NTERA-wt cells (Figure 2A and B)
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Figure 1. AHR knockdown impairs RA-induced differentiation. (A) NTERA-wt and AHR knockdown NTERA-sh cells were grown in 2D cultures and
clone formation analyzed 48 h later in absence (UT) or presence of 1 M RA. (B) Both cell lines were left untreated (UT) or treated with 1 M RA for
48 h. Total cell extracts were analyzed for the expression of neuronal markers Tau, III-tubulin and GAP43 by immunoblotting. GAPDH was used to
normalize protein expression. (C) Tau, III-tubulin and GAP43 were also analyzed by immunofluorescence in untreated (UT) or RA-treated NTERA-wt
and NTERA-sh cells using a Fluoview FV1000 confocal microscope. (D) NTERA-wt and NTERA-sh cells were left untreated or treated with 1 MRA
for 72 h and total AHR protein levels determined by immunoblotting. -Actin was used as normalization control. Panels A–D: n= 4 biological replicates.
*P < 0.05 and **P < 0.01. Data are shown as mean ± SD.
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Figure 2. RA-induced differentiation translocates AHR to the cell nucleus and represses OCT4 and NANOG. (A) NTERA-wt and NTERA-sh cells were
left untreated or treated with 1 M RA for 72 h. Cytosolic and nuclear extracts were prepared and analyzed for the presence of AHR in each cellular
compartment by immunoblotting. GAPDH and RNA polIII were used as cytosolic and nuclear controls, respectively. (B) The intracellular distribution of
AHR was determined by immunofluorescence in NTERA-wt and NTERA-sh cells left untreated or treated with 1 MRA for 72 h in absence (UT) and
presence of 1 M RA. (C and D) NANOG and OCT4 mRNAs were quantified by RT-qPCR in both cell lines left untreated (UT) or treated with 1 M
RA for 48 or 72 h. GAPDH mRNA was used to normalize gene expression (Ct) and 2−Ct to calculate variations with respect to control or untreated
conditions. (E) OCT4 protein levels were analyzed by immunoblotting and normalized by GAPDH. (F) The effects of RA on OCT4 and NANOG protein
expression were also determined in NTERA-wt and NTERA-sh cells by immunofluorescence. Panels A–D: n = 4 biological replicates; panels E–F: n = 6,
two technical replicates in three biological replicates. *P < 0.05 and **P < 0.01. Data are shown as mean ± SD.
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but had a negligible effect in AHR-interfered cells, which
maintained their very low basal levels of AHR (Figure
2A and B). To further analyze the implication of AHR in
RA-induced differentiation, we performed long-term RA
treatment (e.g. 4 weeks) of NTERA-sh cells. Under persis-
tent differentiating conditions, AHR protein levels gradu-
ally increased and NTERA-sh cells acquired wild-type-like
clone morphology and the expression of neuronal mark-
ers Tau and III-tubulin (Supplementary Figure S2A and
B). Restoration of a differentiation response in NTERA-sh
cells by AHR re-expression supports a role for AHR in pre-
serving teratocarcinoma cell differentiation.
To address that hypothesis, we first analyzed whether the
effects of AHR on cell differentiation were mediated by
changes in the expression of pluripotency genes. RA treat-
ment of NTERA-wt cells produced a large reduction in
mRNA levels of the stemness-related genes NANOG and
OCT4 (Figure 2 C and D, and Supplementary Figure S3A
and B) without a significant effect on SOX2 and NOTCH1
(Supplementary Figure S3C and D). In agreement, pro-
tein levels of OCT4 and NANOG were also reduced by
RA treatment in NTERA-wt cells as determined by flu-
orescence confocal microscopy and western-blot analyses
(Figure 2E and F). In contrast, NTERA-sh cells had in-
creased levels of OCT4 and NANOG mRNA and protein
under basal conditions and, importantly, they were less sen-
sitive to RA treatment (Figure 2C–F). To further support
the implication of AHR in OCT4 and NANOG repression,
we did treatments with the AHR ligand 6-formylindolo[3,2-
b]carbazole (FICZ) in absence of RA (33). FICZ decreased
OCT4 and NANOG mRNA levels in untreated NTERA-
wt cells (Supplementary Figure S3E and F) but not in
NTERA-sh cells (Supplementary Figure S3G and H), sug-
gesting that AHR is involved in the mechanism that regu-
lates OCT4 and NANOG during the differentiation of hu-
man carcinoma cells.
Pluripotency genes contain Alu retrotransposons in their up-
stream regulatory regions that are transcribed upon differen-
tiation
Bioinformatic analyses have identified thousands of po-
tential AHR binding sites (XRE; Xenobiotic Respon-
sive Element) dispersed throughout the Human Genome
(14,16,34). However, their functional and biological signif-
icance remains to be determined. Using a previously de-
veloped Perl script (14), we have identified XRE sites for
AHR binding that happen to be included within repetitive
sequences that are located in the promoter of pluripotency
genes NANOG, OCT4, SOX2 and KLF4. These repetitive
elements have been assigned to the family of Alu-S retro-
transposons having an XRE / E-box motif similar to that
found in murine SINE-B1 repeats (14) (Figure 3A). Alu el-
ements in the NANOG, SOX2 and KLF4 promoters belong
to the Sx subfamily whereas the OCT4-Alu is included in
the Sq subfamily of human retroelements (Figure 3A). Im-
portantly, these Alus contain A and B boxes and a puta-
tive transcription start site for RNA polymerase III (RNA
polIII)-dependent transcription and at least one XRE site
for AHR binding (Figure 3B, NANOG and OCT4 Alus are
shown). This sequence analysis suggested that these Alus
could control the expression of their hosting genes through
the transcription factor AHR.
We considered the possibility that transcription of the
Alu elements present in the promoter of these pluripotency
genes could repress their expression to induce differentia-
tion of carcinoma cells. We focus our study on NANOG
and OCT4 since they were the genes more significantly
affected by RA treatment in NTERA cells in an AHR-
dependent manner (see Supplementary Figure S3). Tran-
scription of Alu retrotransposons was analyzed by deep
sequencing of small RNA molecules (RNAseq) isolated
from NTERA-wt and NTERA-sh cells under basal and
RA-differentiated conditions. Raw RNAseq data have been
deposited in the Sequence Read Archive (SRA, NCBI)
with submission number PRJNA301447. Previouswork has
shown that RNAseq is a useful tool to identify transcripts
produced from individualAlu elements byRNApolIII (35).
To avoid sequencing mRNAs and long non-coding RNA
transcripts, libraries were made using size-selected small
RNA populations (Supplementary Figure S4A, ncRNA).
Bioinformatic alignment of theRNAseq data againstOCT4
and NANOG Alus identified transcripts produced from the
OCT4-Alu (hereafterOCT4Alu-T) andNANOG-Alu (here-
after NANOG Alu-T1 and Alu-T2) under basal conditions
in NTERA-wt cells (Figure 3C). Notably, the level of those
transcripts was significantly increased by RA-induced dif-
ferentiation in NTERA-wt cells but not in NTERA-sh
cells (Figure 3C). Importantly, the level of NANOG and
OCT4 Alu-derived transcripts was significantly higher than
the predicted background level between AluSq and AluSx
elements (Figure 3C, black dotted line). We have previ-
ously found that transcription of an AhR-regulated murine
SINE-B1 retrotransposon takes place mainly in the anti-
sense orientation (15). Similarly, the analysis of RNAseq
data indicated that bothOCT4 andNANOGAluswere pref-
erentially transcribed in the antisense direction, despite the
presence of sense transcripts produced from the NANOG
Alu (Figure 3D).
AHR and RNA polIII are involved in OCT4 and NANOG
repression in differentiated carcinoma cells
Most human Alus are transcribed by RNA polIII, which
can be inhibited by the molecules tagetitoxin (TGT) (36)
andWYE132 (37). TGT treatment significantly blocked the
repression of NANOG and OCT4 produced by RA at the
mRNA level in NTERA-wt cells (Figure 4A). Control ex-
periments showed that TGT was a potent RNA polIII in-
hibitor in NTERA cells able to efficiently inhibit Leu tRNA
expression (Figure 4B). In addition, NTERA-wt cells had a
similar response to WYE132, which could also efficiently
block the repression of NANOG and OCT4 by RA (Sup-
plementary Figure S4B). WYE132 was an RNA polIII in-
hibitor in NTERA cells since it could repress Leu tRNA ex-
pression (Supplementary Figure S4C) without significantly
affectingNANOG andOCT4mRNAs in the absence of RA
treatment (e.g. WYE132 did not inhibit RNA polII) (Sup-
plementary Figure S4D). Thus,NANOG andOCT4 repres-
sion in differentiatedNTERA cells appears to require AHR
upregulation and the transcriptional activation of their Alu
elements by RNA polIII. In agreement with such possibil-
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Figure 3. HumanOCT4 andNANOG genes contain Alu retrotransposons in their promoters harboring AHR and RNA polIII binding sites. (A) Sequence
analysis was used to determine the distribution of Alu retrotransposons among the Alu-Sx (NANOG, SOX2 and KLF4) or Alu-Sq (OCT4) subfamilies.
(B) The full-length sequences of NANOG-Alu-Sx and OCT4-Alu-Sq were analyzed for the presence of XRE sites for AHR binding and A and B boxes
for RNA polIII-dependent transcription. A DR2 box was also found in the NANOG-Alu. OCT4 and NANOG Alus contained the putative +1 adenosine
nucleotide for RNA polIII transcription. The algorithm used for the bioinformatics analysis has been described (14). (C) Non-coding RNA libraries were
prepared and sequenced as indicated in Supplementary Figure S4A. The bulk of reads obtained from each library was aligned with the sequences ofOCT4
andNANOG Alus. Transcripts frequently expressed in NTERA-wt (blue) or NTERA-sh (red) in absence (UT) or presence of 1 MRA appeared as peaks
overlapping the sequence of each Alu element. The baseline expression of human AluSq and AluSx transposons is indicated by a horizontal black dotted
line. (D) The sense (red line) and antisense (black line) orientation of the transcripts produced from the NANOG and OCT4 Alus was determined from the
RNAseq dat. Transcripts showing complementary for either the sense or the antisense strand were plotted against the full-length Alus to produce peaks
corresponding to the NANOG Alu-T1 and Alu-T2 and OCT4 Alu-T molecules.
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Figure 4. OCT4 andNANOGAlus bind AHR, are transcribed by RNA polIII in differentiated cells. (A)NANOG andOCT4mRNA levels were quantified
in NTERA-wt cells left untreated (UT), treated with 1 mMRA or with 1 mMRA+ 10mM tagetitoxin (TGT) for 48 h. (B) Leu tRNA levels were measured
in NTERA-wt cells untreated (UT) or treated with 1 mM RA + 10 mM TGT for 48 h. (C) Chromatin immunoprecipitation (ChIP) for AHR and OCT4
binding to the NANOG and OCT4 Alus was done in NTERA-wt cells left untreated (UT) or treated with 1 M RA for 48 h. For specificity, one primer
for the PCR reaction to amplify each Alu was located in a unique genomic sequence flanking the transposon (see Supplementary Table S1). Double ChIPs
involved a first immunoprecipitation with anti-OCT4 followed by a second immunoprecipitation with anti-AHR antibody. NTERA-sh cells were used
as negative controls. Input DNAs and immunoprecipitations done in absence of specific antibodies were also performed. (D and E) NANOG and OCT4
Alu-derived transcripts were quantified by RT-qPCR in absence (UT) or presence of 1 M RA using the conditions described in Supplementary Figure
S5A-C. (F) Basal levels of NANOG Alu-T1 and Alu-T2 and OCT4 Alu-T were measured in NTERA-wt cells by RT-qPCR. GAPDH mRNA was used to
normalize gene expression (Ct) and 2−Ct to calculate variations with respect to control or untreated conditions. Panels A and B: n = 6, two technical
replicates in three biological replicates; panel C: n = 4 biological replicates; panels D-F: n = 4, two technical replicates in two biological replicates. *P <
0.05, **P < 0.01 and ***P < 0.001. Data are shown as mean ± SD.
ity, sequence analysis revealed thatOCT4 andNANOGAlus
contain the core motifs present in most active AluS sub-
families (Supplementary Figure S4E) (17). Furthermore,
both NANOG and OCT4 Alus were able to retrotranspose
in HeLa cells as determined using an established Alu engi-
neered assay (25,38) (data not shown).
As AHR is a transcription factor, we next tested if the
repression of NANOG and OCT4 required AHR binding
to the XRE sequences present in their upstream Alu ele-
ments (Figure 3B). ChIP experiments in NTERA-wt cells
using genomic region-specific primers showed that, under
basal conditions, AHR was present in the OCT4 Alu but
not in theNANOGAlu (Figure 4C). Upon RA-induced dif-
ferentiation, AHR was recruited to the NANOG-Alu and
released from the OCT4 Alu (Figure 4C). Interestingly, se-
quential double AHR + OCT4 ChIP revealed that OCT4
and AHR were recruited together to the NANOG-Alu in
RA-differentiated NTERA-wt cells (Figure 4C). A negligi-
ble interaction of AHR with the NANOG-Alu (Figure 4C)
or the OCT4 Alu (not shown) was found in basal or RA-
treated NTERA-sh cells. These results indicate that AHR
binds to the NANOG Alu in differentiated cells and that
AHR could be part of a transcriptional complex that also
includes OCT4.
TheNANOG andOCT4 Alu elements are transcribed during
differentiation
Based on the apparent prevalence of defined transcripts in
differentiated NTERA cells (Figure 3C), we next used the
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RNAseq data to assess which amplicons may be used to
detect the expression of NANOG and OCT4 Alus. Consid-
ering the repetitive nature of Alu elements, we first inter-
rogated the Human Genome for the presence of instances
identical to either NANOG or OCT4 Alus. At the current
sequence resolution of the HumanGenome, we did not find
any other Alu elements fully homologous to those present
inNANOG andOCT4 promoters. Based on this finding, we
then decided to map putative sites in the Human Genome
having full sequence identity with the transcripts produced
from the NANOG and OCT4 Alus. This approach would
give us an accurate estimation on to what extent those tran-
scripts were produced from the NANOG and OCT4 Alus
(since both elements appear at unique locations in the Hu-
manGenome) and not from other related retrotransposons.
Interestingly, the amplicons predicted by RNA-seq analy-
sis (Figure 3C) were also unique in the Human Genome
for the case ofNANOG Alu-T1 and Alu-T2 in chromosome
12 (Figure 5, full length hit and asterisks) and OCT4 Alu-
T in chromosome 6 (Figure 5, full length hit and aster-
isks). Moreover, NCBI Blast analysis predicted partial se-
quence similarity with only 10 and 21 more Alu elements
for NANOG Alu-T1 and Alu-T2 and with 214 more Alu el-
ements in the case of OCT4, respectively (Figure 5). Based
on these results, transcript-specific RT-qPCR assays were
designed to quantify the expression ofOCT4- andNANOG-
Alu-derived transcripts (Supplementary Figure S5A andB).
Amplicons were selected to cover the T1 (yellow) and T2
(red) transcripts from the NANOG Alu and the T (cyan)
transcript from theOCT4Alu (SupplementaryFigure S5C).
Capillary fluorescent dideoxi-sequencing was used to con-
firm the identity of the amplicons obtained by qPCR (Sup-
plementary Figure S5D). The results obtained indicated
that NANOG Alu-T1 and Alu-T2 (Figure 4D) and OCT4
Alu-T (Figure 4E) were significantly upregulated by RA in
NTERA-wt but not in NTERA-sh cells. In addition, the
OCT4 Alu-T was expressed at much lower levels than the
NANOG Alu-T1 and Alu-T2 under basal cell conditions
(Figure 4F).Moreover, treatment with TGTorWYE132 re-
duced the levels of OCT4 Alu-T, NANOG Alu-T1 and Alu-
T2 transcripts in untreated NTERA-wt cells, further sup-
porting the implication of RNA polIII in the transcription
of OCT4 and NANOG Alus (Supplementary Figure S5E).
We next investigated the role of AHR in OCT4 and
NANOG transcription. As a first approach, we treated
NTERA cells with the AHR non-toxic ligand FICZ. AHR
activation by FICZ increased the levels of NANOG Alu-
T1 and Alu-T2 and OCT4 Alu-T transcripts in NTERA-
wt cells (Supplementary Figure S6A–C), supporting a role
for this receptor in the regulation of these non-coding RNA
transcripts. The effect was transient and each Alu-derived
transcript returned to its basal level 24 h after FICZ treat-
ment (Supplementary Figure S6A–C). Consistently, ChIP
experiments showed that FICZ was able to induce AHR
binding to the NANOG Alu in NTERA-wt cells to a level
similar to that produced by RA treatment (Supplementary
Figure S6D). Surprisingly, FICZ was also a potent inducer
of OCT4 binding to theNANOGAlu, reaching levels signif-
icantly higher that those obtained by RA (Supplementary
Figure S6D).
We then decided to rescue AHR expression in AHR
knockdown cells to investigate if restoring AHR could in-
crease the content in Alu-derived transcripts while reduc-
ing the levels of NANOG and OCT4 mRNAs (Figure 6).
To do that, NTERA-wt cells were retrovirally engineered
to stably express an shRNA molecule targeting the 3′UTR
of the human AHR (NTERA-sh 3′UTR); this approach al-
lowed transfection of a human AHR coding sequence not
targeted by the 3′UTR shRNA molecule (Supplementary
Table S1). NTERA-sh 3′UTR cells had an almost complete
loss of AHR expression, increased basal protein levels of
OCT4 and very low expression of neuronal markers III-
tubulin and Tau, consistent with the results presented above
(Figure 6A). Similar data were obtained using two different
shRNAmolecules and two different pools of NTERA cells,
excluding potential off-target effects in the observed phe-
notype. Restoring AHR expression in NTERA-sh 3′UTR
cells by transient transfection mimicked the effects induced
by RA with respect to the expression of OCT4 and the
neuronal differentiationmarkersIII-tubulin andTau (Fig-
ure 6A). Control experiments showed that AHR produced
from the transfected plasmid was transcriptionally active
in NTERA-sh 3′UTR cells based on the induction of its
canonical target gene CYP1A1 (Figure 6B). In agreement
with data shown above, rescuing AHR expression, in ab-
sence of RA treatment, increased the levels ofNANOGAlu-
T1 andAlu-T2 (Figure 6C andD) and repressed themRNA
expression of OCT4 and NANOG (Figure 6E and F) in
NTERA-sh 3′UTR cells. Moreover, transient transfection
of AHR in wild-type NTERA cells further increased the
levels ofNANOGAlu-derived transcripts (Figure 6C andD)
and strongly repressedOCT4 andNANOGmRNAs (Figure
6E and F). Altogether, these results provide evidences that
transcripts produced fromAlu elements located upstreamof
NANOG andOCT4might be involved in controlling the ex-
pression of these genes during differentiation of carcinoma
cells.
Transcription of the NANOG Alu from its RNA polIII pro-
moter represses OCT4 and NANOG in absence of RA
We next considered the possibility that the transcripts pro-
duced from theNANOG andOCT4 Alus could regulate the
expression of their respective genes in absence of RA. To do
that, each Alu element was cloned in a promoter-less plas-
mid (pUC57) to allow transcription from its internal RNA
polIII promoter (Figure 3B, A and B boxes). We first con-
firmed by RT-qPCR that the OCT4 and NANOG-Alu con-
structs specifically expressed the corresponding Alu-T and
Alu-T1 and Alu-T2 transcripts, respectively (Figure 7A).
Remarkably, whereas transfection of theOCT4-Alu did not
repress OCT4 nor NANOG in NTERA-wt cells, expression
of the NANOG-Alu efficiently repressed the mRNA lev-
els of both genes (Figure 7B and C), suggesting that tran-
scripts produced from the NANOG Alu could potentially
act in cis and trans to regulate NANOG and OCT4 expres-
sion. To provide additional support for the role of NANOG
Alu-derived transcripts in regulating OCT4 and NANOG,
we have introduced site-specific mutations in the XRE sites
and in the A and B boxes for AHR and RNA polIII
binding, respectively (Figure 7D). The selected mutations
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Figure 5. Full length NANOG and OCT4 Alu-derived transcripts map to their specific genomic locations. The complete sequence of the NANOG Alu-
T1 and Alu-T2 and OCT4 Alu-T transcripts were aligned against the Human Genome to identify their fully homologous locations in each chromosome
(100% sequence homology, full length hit, asterisk). Full length NANOG Alu-T1 and Alu-T2 map to chromosome 12 whereas full length OCT4 Alu map
to chromosome 6. A similar analysis was done reducing the percentage of sequence homology of each Alu-derived transcript and the Human Genome
(partial hit).
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Figure 6. Rescuing AHR expression in AHR knockdown cells restores the
expression of NANOG Alu-derived transcripts and represses OCT4 and
NANOG. (A) NTERA wild-type cells were retrovirally transduced to sta-
bly express a shRNA directed against the 3′UTR of the human AHR. The
resulting NTERA-sh 3′UTR cell line was left untreated (UT), treated with
1 MRA for 72 h (RA) or transfected with a humanAHR expression vec-
tor (AHR). Total protein extracts were examined for AHR, OCT4, III-
tubulin andTau expression by immunoblotting.NTERA-wt cells were also
analyzed in parallel experiments. -Actin was used to normalize protein
expression. (B) The expression of the AHR target gene CYP1A1 was de-
termined by RT-qPCR. (C–F) NTERA-wt and NTERA-sh 3′UTR cells
were treated as above and the levels of NANOG Alu-T1 (C), NANOG Alu-
T2 (D), OCT4 mRNA (E) and NANOG mRNA (F) quantified by RT-
qPCR.GAPDHmRNAwas used to normalize gene expression (Ct) and
2−Ct to calculate variations with respect to control or untreated condi-
tions. Panel A: n = 4, two technical replicates in two biological replicates;
panels B–F: n= 6 two technical replicates in three biological replicates. *P
< 0.05, **P < 0.01 and ***P < 0.001. Data are shown as mean ± SD.
were highly effective in blocking NANOG Alu transcrip-
tion from its internal RNA polIII promoter since the lev-
els of NANOG Alu-T1 and Alu-T2 transcripts were largely
reduced in NTERA-wt cells transfected with the promoter-
less pUC57 vector harboring the XREmut, A + Bmut or
XRE/A + Bmut sequences (Figure 7E). Notably, mutation
of the XRE sites (XREmut), the A and B boxes (A + Bmut)
or both (XREmut/A + B mut) significantly blocked the
ability of theNANOG Alu to repress the mRNA expression
ofNANOG andOCT4 (Figure 7F and G), confirming that,
in the absence of transcription from theNANOGAlu, the re-
pressive mechanismwasmarkedly impaired. Control exper-
iments excluded the possibility that the effects produced by
NANOG andOCT4 Alus were due to changes in AHR pro-
tein levels (Supplementary Figure S6E). In addition, repres-
sion of NANOG and OCT4 was AHR dependent since the
NANOG Alu did not have a significant effect in NTERA-
sh cells (Supplementary Figure S7A,B). Importantly, AHR-
and RNA polIII-dependent transcription of the NANOG
Alu may not have a general impact on pluripotency genes
since it did not alter themRNA levels of the reprogramming
factor SOX2 (39) (Supplementary Figure S7C), the stem-
cell factor and OCT4 regulator LIN28 (40) (Supplementary
Figure S7D) or the pluripotency-inducing factor NR5A2
(41) (Supplementary Figure S7E). Moreover, even though
the 3′UTR regions of LIN28 and NR5A2 have significant
sequence homology with NANOG Alu-derived transcripts,
their mRNA expression did not change by theNANOGAlu
in NTERA-wt cells, further suggesting a specific effect on
the NANOG mRNA.
We then decided to analyze if AHR could also modulate
OCT4 and NANOG expression and the levels of NANOG
Alu-derived transcripts in non-transformed human ES cells.
To do that, we used H9 human ES cells that were either dif-
ferentiated with RA (42,43) or transiently transfected with
a sh-AHR against AHR. H9 cells treated with RA signif-
icantly increased their AHR protein levels while markedly
decreased their OCT4 and NANOG protein content (Sup-
plementary Figure S8A). Downmodulation of pluripotency
factors OCT4 and NANOG likely arose from a significant
reduction in their mRNA levels after RA treatment (Sup-
plementary Figure S8B). Importantly, RA treatment largely
increased the expression of the Alu-T1 and Alu-T2 tran-
scripts derived from the NANOG Alu while moderately en-
hanced the amount of the OCT4 Alu-T transcript (Sup-
plementary Figure S8C). Next, H9 cells were transiently
transfected with the same sh-AHR construct used to gen-
erate the stable NTERA-sh cell line analyzed above. AHR
knockdown produced a significant increase in the protein
levels of both OCT4 and NANOG as compared to wild-
type H9 cells (Supplementary Figure S9A). Consistently,
AHR downmodulation upregulated the mRNA levels of
both genes in H9 cells (Supplementary Figure S9B). Fur-
thermore, a transient reduction in AHR expression de-
creased the levels ofNANOGAlu-T1 andAlu-T2 transcripts
without having a significant effect in the OCT4 Alu-T tran-
script (Supplementary Figure S9C). Therefore, AHR ap-
pears to be able to regulate pluripotency factors OCT4 and
NANOG and the expression of transcripts derived from the
NANOG and OCT4 Alus not only in tumorigenic NTERA
cells but also in untransformed H9 human ES cells.
NANOG andOCT4 repression by Alu-derived transcripts in-
volves the miRNA machinery
Previous studies have shown that the component of
the miRNA pathway Microprocessor (DGCR8 and
DROSHA) can bind transcripts produced from Alu and
LINE-1 (long interspersed element-1) retrotransposons
(25). It is also known that small non-coding RNAs pro-
duced by DICER/AGO3 from Alus containing the DR2
motif can modulate the proliferation of human stem cells
(44). A DR2 element is defined as a 6-bp direct repeat of
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Figure 7. NANOG Alu represses NANOG and OCT4 expression in the absence of RA through AHR and RNA polIII. (A) NANOG and OCT4 Alus were
individually transfected in NTERA-wt cells and the levels of NANOG Alu-T1, Alu-T2 and OCT4 Alu-T transcripts determined by RT-qPCR. (B and C)
A promoter-less pUC57 expression vector containing the NANOG or OCT4 Alus was transfected in NTERA-wt cells and the mRNA levels of NANOG
and OCT4 determined by RT-qPCR. RA was used as positive control. (D) Mutations introduced in the NANOG Alu to inactivate the XRE sites for
AHR binding (cyan), the A (yellow) and B (green) boxes for RNA polIII or a combination of all of them. (E) NANOG Alu mutant constructs for AHR
binding (XREmut), RNA polIII binding (A + Bmut) or both (XRE/A + Bmut) were transfected in NTERA-wt cells and the levels of NANOG Alu-T1
and Alu-T2 quantified by RT-qPCR. (F and G) Mutant constructs for the XRE sites and/or the A and B boxes in the NANOG Alu were cloned in the
promoter-less pUC57 plasmid and transfected in NTERA-wt cells. Wild-type NANOG Alu (wt) and the empty plasmid (EV) were also transfected as
controls. The mRNA levels of NANOG (F) and OCT4 (G) were analyzed by RT-qPCR. Wild-type NANOG Alu (wt) and the empty plasmid (EV) were
used as experimental controls.GAPDHmRNAwas used to normalize gene expression (Ct) and and 2−Ct to calculate variations with respect to control
or untreated conditions. Panels A-C; E-G: n = 6, two technical replicates in three biological replicates. *P < 0.05, **P < 0.01 and ***P < 0.001. Data are
shown as mean ± SD.
the retinoid acid receptor (RAR) binding site spaced by 2
nt (44). Based on these previous studies, we investigated
whether the miRNA machinery was involved in the Alu-
dependent regulation of NANOG and OCT4. First, we
treated NTERA-wt cells with the RISC (RNA-induced
silencing complex) inhibitor ATA (aurintricarboxylic acid)
(45) and found that ATA significantly prevented the repres-
sion of NANOG and OCT4 caused by RA (Figure 8A and
B). Consistent with the implication ofNANOG Alu-derived
transcripts in the mechanism, inhibition of the miRNA
machinery by ATA also increased the levels of NANOG
Alu-T1 and NANOG Alu-T2 in NTERA-wt cells treated
with RA (Figure 8C and D). Next, we transfected plasmids
expressing dominant-negative forms of DROSHA and
DGCR8 in NTERA-wt cells and observed that blockade
of these proteins rescued the repression of NANOG and
OCT4 produced by the NANOG Alu in absence of RA
(Figure 8E and F). Control experiments confirmed that
dominant-negative forms of DROSHA and DGCR8
efficiently inhibited the miRNA pathway based on the
accumulation of the pre-miR-24-1 (Supplementary Figure
S7F). Collectively, these data suggest that transcripts pro-
duced from the NANOG Alu may act through the miRNA
pathway to control NANOG and OCT4 expression, and
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Figure 8. RISC inhibition and microprocessor knockdown rescues NANOG and OCT4 expression likely through loading of NANOG Alu-derived tran-
scripts into AGO2. (A and B) NTERA-wt cells were left untreated (UT), treated with 25 M ATA (aurintricarboxylic acid) or with 1 M RA + 25 M
ATA and the expression of NANOG (A) and OCT4 (B) determined as above. (C and D) NTERA-wt cells were left untreated (UT), treated with 25 M
ATA or with 1 M RA + 25 M ATA and the expression of NANOG Alu-T1 (C) and Alu-T2 (D) determined by RT-qPCR. The oligonucleotides used
are indicated in Supplementary Table S1. (E and F) The NANOG Alu was transfected in NTERA-wt cells with or without dominant-negative forms of
DROSHA or DGCR8 and their effects on NANOG (E) and OCT4 (F) expression analyzed by RT-qPCR. (G) RNA was extracted from NTERA-wt cells
and RNA immunoprecipitations (RIP) for NANOG Alu-T1 and Alu-T2 and OCT4 Alu-T transcripts performed using an anti-AGO2 antibody. RIP was
quantified by qPCR using the oligonucleotides indicated in Supplementary Table S1. GAPDH mRNA was used to normalize gene expression (Ct) and
2−Ct to calculate variations with respect to control or untreated conditions. Panels A and B: n= 6, two technical replicates in three biological replicates;
panels C and D: n = 6, two technical replicates in three biological replicates; panels E and F: n = 4, two technical replicates in two biological replicates;
panel G: n = 4, two technical replicates in two biological replicates. *P < 0.05, **P < 0.01 and ***P < 0.001. Data are shown as mean ± SD.
that such process requires miRNA pathway components
RISC and Microprocessor.
As mentioned above, the DR2 element appears to be rel-
evant for loading Alu-derived transcripts into the miRNA
machinery via AGO3 (44). Since the NANOG Alu has a
DR2 sequence (Figure 3B), we next tested whether AGO
proteins could bind RNA transcripts produced from the
NANOG and OCT4 Alus. RIP followed by RT-qPCR
showed that NANOG Alu-T1 and Alu-T2 and OCT4 Alu-T
transcripts were loaded into the RISC component AGO2,
and that loading increased upon differentiation ofNTERA-
wt cells (Figure 8G). Interestingly, cuantitative RNA anal-
ysis revealed a very low efficiency of OCT4 Alu-T loading
into AGO2 even under RA-induced differentiation. Load-
ing of NANOG Alu-T1 and Alu-T2 transcripts into AGO2
increased with time for at least 48 h after RA treatment
(Supplementary Figure S7G).
Certain TEs, including Alu retrotransposons, can regu-
late the generation of miRNAs (e.g. Let-7) known to be
involved in cellular differentiation (46–48). The analysis
of pre-miRNA expression revealed that differentiation re-
duced the levels of pre-Let-7 and increased pre-miR-21,
pre-miR-424, pre-miR371 and pre-miR-141 in NTERA-wt
but not in NTERA-sh cells (Figure 9A). Interestingly, time
course experiments showed that NANOG Alu-T1 and Alu-
T2 transcripts appeared early during differentiation (e.g. 24
h) whereas those pre-miR molecules reached their maxi-
mum levels only after 72 h of RA treatment (Figure 9B),
suggesting that transcription of NANOG Alu-derived tran-
scripts probably precedes the accumulation ofmiRNAs that
could cooperate to control the differentiation of NTERA
cells.
These results lead us to consider that NANOG Alu-T1
and Alu-T2 transcripts, loaded into AGO2, could target
complementary sequences in the mRNAs of NANOG and
OCT4. Sequence analysis revealed that NANOG Alu-T1
and Alu-T2 transcripts were highly homologous to the
3′UTR of NANOG and significantly homologous to the
3′UTR of OCT4 (Supplementary Figure S10A and B).
Conditional training analysis for the prediction of RNA
secondary structures (CONTRAfold) revealed the optimal
conformation of NANOG Alu-T1 and Alu-T2 transcripts
in their homology regions with the 3′UTR of NANOG
and OCT4 (Supplementary Figure S10C and D). Impor-
tantly, sequence analyses by RepeatMasker (http://www.
repeatmasker.org) revealed that the 3′UTR ofNANOG har-
bors an AluY element homologous to NANOG Alu-T1 and
Alu-T2 transcripts. However, the 3′UTR of OCT4 did not
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Figure 9. NANOG Alu-derived transcripts could act through a miRNA mechanism to control NANOG and OCT4 repression during differentiation. (A)
NTERA-wt and NTERA-sh cells were left untreated (UT) or treated with 1 MRA for 48 h and the levels of pre-miRs pre-Let7, pre-miR-21, pre-miR-424,
pre-miR-371, pre-miR-141 quantified by RT-qPCR using the oligonucleotides indicated in Supplementary Table S1. (B) Both cell lines were treated with
1 M RA for the indicated times and the levels of NANOG Alu-T1 and Alu-T2, pre-Let7, pre-miR-21 and pre-miR-141 determined by RT-qPCR. (C) A
NANOG 3′UTR-Luc construct and their deletion mutants lacking the homology regions forNANOG Alu-T1 (T1 mut), Alu-T2 (T2 mut) or both (T1 + T2
mut) were co-transfected with the NANOG Alu in NTERA-wt cells. Firefly luciferase activity was measured and normalized by renilla luciferase. Control
experiments were done in presence of RA (dashed). (D) NTERA-wt and NTERA-sh cells were injected subcutaneously in immunodeficient Swiss nude
mice (Charles River) and the tumors formed collected and analyzed by immunohistochemistry using endodermal (pan-cytokeratins and -fetoprotein),
mesodermal (-smooth muscle actin) and ectodermal (glial fibrilar acidic protein, GFAP) markers. Immunohistochemistry sections were analyzed blinded
by eight independent observers and protein expression quantified in a 0–10 scale. Arrowheads indicate positivity areas used to estimate protein expression.
(E) Scheme of the mechanism proposed for the Alu-dependent repression of NANOG and OCT4 during carcinoma cell differentiation. GAPDH mRNA
was used to normalize gene expression (Ct) and 2−Ct to calculate variations with respect to control or untreated conditions. Panels A and B: n = 6,
three technical replicates in two biological replicates; panel C: n = 4, two technical replicates in two biological replicates; panel D: n = 4 mice for each cell
line. *P < 0.05, **P < 0.01 and ***P < 0.001. Data are shown as mean ± SD.
contain Alu-derived sequences despite its partial homol-
ogy withNANOG Alu-T1 and Alu-T2 (Supplementary Fig-
ure S10A,B). Other genes involved in differentiation but
not regulated by Alu-derived transcripts such as SOX2 and
NOTCH1 did not contain Alu-derived sequences in their
3′UTR regions, nor homology with NANOG Alu-T1 and
Alu-T2. These findings suggested that theAlu present in the
3′UTR region ofNANOG could interact withNANOGAlu-
derived transcripts to repress NANOG expression in differ-
entiated cells.
To analyze if NANOG Alu could regulate NANOG
3′UTR, we cloned the wild-type NANOG 3′UTR and its
mutant forms lacking the homology regions for NANOG
Alu-T1 and Alu-T2 transcripts in a luciferase reporter vec-
tor (Supplementary Figure S7H). Transfection of NTERA-
wt cells withNANOGAlu in absence ofRA repressed the ac-
tivity of the wild-type NANOG 3′UTR-Luc construct (Fig-
ure 9C). However, the NANOG Alu was unable to repress
the activity of NANOG 3′UTR-Luc mutants lacking the
homology regions for Alu-T1, Alu-T2 or both transcripts
(Figure 9C). These data led us to speculate that NANOG
Alu might regulate NANOG and OCT4 at the mRNA level
through themiRNApathway. Consistent with this hypothe-
sis, bioinformatic studies have suggested thatAlu sequences
located in the 3′UTR region of certain mRNAs can be rec-
ognized by miRNAs to regulate target gene expression (49).
AHR knockdown increases the formation of undifferentiated
teratomas
We finally decided to validate AHR as a differentiation fac-
tor in human carcinoma cells using an in vivo teratoma as-
say. NTERA-wt and NTERA-sh cells were xenografted in
immunocompromised Swissmice and the teratomas formed
analyzed for the presence of the three embryonic layers
(39). Using this assay, we found that NTERA-wt cells gen-
erated teratomas containing endodermal (pan-cytokeratin
and -fetoprotein), mesodermal (-smooth muscle actin)
and ectodermal (glial fibrilar acidic protein, GFAP) embry-
onic layers (Figure 9D). Teratomas formed by NTERA-
sh cells had significantly higher expression of endoder-
mal, mesodermal and ectodermal markers than NTERA-
wt cells (Figure 9D), suggesting that AHR depletion led to
a more undifferentiated phenotype and an increased abil-
ity to differentiate in vivo. It is reasonable to assume that
such properties of NTERA-sh cells might be due, at least in
part, to their increased expression of pluripotency factors
NANOG and OCT4. Notably, our hypothesis is in agree-
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ment with recent studies showing that in vivo reprogram-
ming induces undifferentiated teratomas with increased ex-
pression of NANOG (50), and that OCT4 has a major role
in reprogramming and in the generation of iPS cells (51).
DISCUSSION
TEs, including LINEs, SINEs and human Alus, are
widespread in mammalian genomes and, although their
contribution to genome evolution and dynamics is now gen-
erally accepted, very limited knowledge is available regard-
ing their contribution to gene regulation and cell function
(2,52). Alu retrotransposons derive from the 7SL RNA and
are the most abundant TEs in the Human Genome. Among
the different Alu lineages known, some ancient genomic
AluS contain an active core sequence in terms of retrotrans-
position ability (17). In addition, it has been suggested that
they could be active in somatic tissues as the human brain
(53,54). Furthermore, there is an increasing interest in iden-
tifying Alu elements whose activation could contribute to
human disease, such as that inserted into the ANRIL long
non-coding RNA (7).
In this study, we have presented data suggesting that
the dioxin receptor AHR regulates the transcription of
Alu elements located in the upstream promoter regions of
the pluripotency genes NANOG and OCT4, and that Alu-
derived transcripts probably repress the expression of both
genes in differentiated carcinoma cells possibly through the
miRNA pathway. Our study therefore integrates the acti-
vation of specific Alu elements in the control of important
cellular functions such as differentiation and pluripotency.
Here, we demonstrate that AHR acts as a differentiation
factor in human embryonic teratocarcinoma cells because
its stable knockdown led to a basal undifferentiated pheno-
type that made cells unresponsive to RA-induced neuronal
differentiation. Furthermore, differentiation increased the
cellular levels of AHR and promoted its nuclear translo-
cation, thus suggesting increased transcriptional activity of
this receptor. The role of AHR in differentiation is also
supported by in vivo experiments, as teratomas produced
byAHR-depletedNTERA cells weremore undifferentiated
than those from AHR-expressing NTERA cells. These re-
sults are consistent with the activation of AHR during dif-
ferentiation of mouse ES cells (31) and with the inhibitory
role of mouse AHR in epithelial-to-mesenchymal transition
(21) and in melanoma primary tumorigenesis and metasta-
sis (20).
AHR has been extensively characterized as a transcrip-
tion factor that binds the promoter region of xenobiotic-
related and xenobiotic-unrelated genes (55). It is remarkable
that AHR can also interact with specific repetitive retro-
transposon sequences such as the murine B1-SINE to trig-
ger the activation of a genomic insulator eventually able
to modulate gene expression (14–16). Binding to TEs ap-
pears to be a conserved property of AHR, as we show here
that it can also directly binds to human AluS retrotrans-
posons located in the promoter region of the pluripotency
genes OCT4 and NANOG. However, a complex interplay
between AHR binding and AluS sequences seems to oc-
curs, since differentiation recruits AHR to theNANOG Alu
while releasing it from the OCT4 Alu. One possible expla-
nation for these results is that the increase in nuclear AHR
that takes place during differentiation could shift the re-
ceptor from the OCT4 to the NANOG Alu, inducing at the
same time the co-recruitment of OCT4 to theNANOG Alu.
This would imply that AHR can cooperate with OCT4 in
repressing NANOG expression and, thus, integrates this re-
ceptor into the proposed ‘pluripotency core regulatory cir-
cuitry’ of transcription factors that also includes SOX2 and
that governs differentiation in human and mouse ES cells
(56–58). In fact, AHR activation by its non-toxic ligand
FICZ produced a robust binding of OCT4 to the NANOG
Alu in absence of RA.
Notably, the repression of Alu-containing OCT4 and
NANOG genes in differentiated NTERA cells is AHR de-
pendent based on the lack of response shown by AHR-
depleted cells, and appears to be specific since it does not
take place in other examined Alu-containing pluripotency
genes such as SOX2, NOTCH1, MYC and KLF4. Impor-
tantly, the repression process seemed to require the syn-
thesis of non-coding RNA molecules since blockade of
RNA polymerase III restored OCT4 and NANOG expres-
sion in an AHR-dependent manner. Notably, and as RNA
polIII may transcribe 7SL RNAs and other non-coding se-
quences (59), we speculated that transcripts derived from
the NANOG and OCT4 Alus could participate in the re-
pression of both genes. Indeed, RNAseq and RT-qPCR ex-
periments revealed that differentiation of NTERA cells in-
creased the levels of transcripts derived from NANOG and
OCT4 Alus, being predominant those synthesized from the
NANOG Alu. In agreement with the gene expression data,
transcription of these Alu elements is AHR dependent be-
cause their levels are upregulated by AHR knockdown in
RAdifferentiated cells and increased byAHRrescue inRA-
untreated cells. Such AHR-dependent mechanism regulat-
ing the expression of OCT4, NANOG and NANOG Alu-
derived transcripts may be operative in non-transformed
human cells since RA treatment and AHR knockdown re-
produced in human H9 ES cells the same regulatory pat-
tern to that observed in embryonic carcinoma NTERA
cells. One important observation is that the Alu retrotrans-
posons located in NANOG and OCT4 promoters have a
high degree of sequence specificity, not been detectable at
additional locations in the Human Genome. This prop-
erty most likely determines that NANOG- and OCT4 Alu-
derived transcripts have full sequence identity and full ho-
mology only to the chromosomal regions where their re-
spective Alus are located and from which they are tran-
scribed. Another relevant finding from this study is that ex-
pression of these Alu elements, by themselves, could reg-
ulate NANOG and OCT4 during carcinoma cell differen-
tiation. We consider this result relevant since a deep tran-
scriptome profiling study has shown that non-coding tran-
scripts derived from long terminal repeats can associate to
enhancers of pluripotency related genes (18,60,61). Never-
theless, the effects of NANOG and OCT4 Alus in gene re-
pression appear to have a significant degree of specificity
regarding not only to the Alu element but also their target
genes. Indeed, expression of NANOG Alu from its endoge-
nous promoter repressed both NANOG and OCT4 mR-
NAs in absence of a differentiation stimulus. In contrast,
expression of OCT4 Alu does not significantly affect either
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gene under the same experimental conditions. Addition-
ally, whereasNANOGAlumost likely regulates theNANOG
gene in cis, its effects on the OCT4 gene could be done
in trans. Such mechanism would resemble the one recently
proposed for the long non-coding RNA ANRIL that regu-
lates atherosclerosis genes in trans by means of an Alu ele-
ment present in its sequence (7). Alternatively, the NANOG
Alu could act onOCT4 by an indirect mechanism involving
signaling through NANOG itself. Nonetheless, this possible
functional connection between NANOG and OCT4 again
supports the ‘pluripotency core regulatory circuitry’ men-
tioned above that would also include AHR (56–58). Finally,
expression of NANOG Alu efficiently repressed NANOG
and OCT4 but not other genes containing similar Alu ele-
ments such as SOX2,LIN28 andNR5A2. Although we can-
not rule out at present time that other Alu loci dispersed in
the Human Genome might contribute to the generation of
additional ncRNAs, when combined with the ChIP data,
our results strongly support that NANOG and OCT4 Alu-
derived transcripts may be involved in the regulation of
pluripotency.
Interestingly, recent studies in rice have shown that the
plant DICER homolog DICER-like 3 can use TE RNAs
to generate small interfering RNAs (siRNA) with the po-
tential to change some agricultural traits of the plant (62).
Similarly, in human cells, the Microprocessor can interact
and process transcripts derived from Alus and LINE-1 to
regulate retrotransposition, although it is not clear whether
processed RNAs give rise to functional miRNAs that might
help to regulate the expression of cellular genes (25). No-
tably, we found that chemical inhibition of the miRNA
pathway by ATA not only rescued OCT4 and NANOG re-
pression in differentiated cells but also increased the ex-
pression of NANOG Alu-T1 and Alu-T2 and OCT4 Alu-
T transcripts. Furthermore, dominant negative forms of
Microprocessor components DROSHA and DGCR8 also
blocked the repression of NANOG and OCT4 induced by
the NANOG Alu in absence of RA. Intriguingly, the in-
teraction between the miRNA pathway and transcripts
derived from retrotransposons could be functionally con-
served since inhibition of theMicroprocessor also increased
the levels of LINE1-derived transcripts and the expression
of their target genes (25).
Although the mechanism by which NANOG and OCT4
Alu-derived transcripts may regulate gene expression re-
quire further experimentation, we speculate that it proba-
bly involves the interaction of Alu-derived transcripts with
the 3′UTR region of the NANOG and OCT4mRNAs. Sev-
eral experiments support this model. First, NANOG Alu-
T1 andAlu-T2 andOCT4 Alu-T transcripts are loaded into
the RISC component AGO2 and such loading significantly
increased with differentiation of NTERA cells. Second, a
marked sequence similarity exists betweenNANOG Alu-T1
and Alu-T2 transcripts and the 3′UTR region of NANOG
and OCT4 mRNAs. Third, the NANOG Alu was able to
regulate the 3′UTR of NANOG but only if the homology
sequences for the Alu-T1 and Alu-T2 transcripts remained
intact. Finally, the levels of miRNAs involved in differen-
tiation such as Let7 and miR141 increased with time by
RA treatment in NTERA-wt but not in NTERA-sh cells
and, interestingly, the expression of NANOG Alu-T1 and
Alu-T2 preceded the accumulation of Let7 and miR141.
It will be interesting to address the processing and iden-
tity of these Alu-derived transcripts and the mechanisms
by which they probably interact with the 3′UTR regions of
both genes. Our working model proposing that the inter-
action of Alu derived-transcripts with 3′UTRs could regu-
late gene expression through the miRNA pathway has been
also considered in previous studies. Indeed, bioinformatic
analyses have shown that certain small RNAs have the po-
tential to target Alu-complementary sequences located in
the 3′UTR of human mRNAs (49). Moreover, the FAN-
TOM4 project has revealed that retrotransposons located
in the 5′ end of mouse and human protein coding genes (as
is the case for NANOG and OCT4 Alus) have the potential
to be transcribed into non-coding RNAs. Importantly, this
study also indicates that a large fraction of the expressed
transcripts that contain retrotransposon complementary se-
quences in their 3′UTRs have lower expression levels than
retrotransposon-free transcripts (63). Accordingly, we have
found that the NANOG mRNA contains an AluY element
in its 3′UTR that is highly homologous with ncRNAs gen-
erated from the AluSx located in the NANOG promoter.
However, the 3′UTR of the OCT4 mRNA has only partial
homology with NANOG Alu-derived transcripts, suggest-
ing the existence of subtle differences in regulation between
both genes.
In sum, we propose that AHR activates the transcription
of Alu retrotransposons located in the NANOG and OCT4
upstream promoter regions in differentiated human carci-
noma cells. Non-coding RNA transcripts produced from
these Alus could repress NANOG and OCT4 expression
probably through the miRNA pathway (Figure 9E). OCT4
and NANOG repression in differentiated cells is AHR and
RNA polIII dependent and, notably, the expression of the
NANOG Alu is able to repress both genes in the absence of
a differentiating stimuli. This regulatory mechanism could
be relevant for normal and tumor cell growth and dissem-
ination. Moreover, the results included in this study reveal
how fixed TEs can participate in Human Genome regula-
tion by a novelmechanism involving non-codingRNAs and
the miRNA pathway (Figure 9E).
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